focus -WSS

focus

author：comprehensive 2025-09-29 21:26:55 - browse：361

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： CDC picks Alphabet's Verily for wasterwater surveillance contract

WSS

The biotech scorecard for Q4: 16 stock

Why a market frenzy over new weight loss drugs defies logic

Congress extends some pandemic preparedness programs

Lawsuit highlights wrinkle for disputes over surprise medical bills

STAT Readout: Friday, Oct. 20 biotech updates

J&J lung cancer data amount to new salvo against AstraZeneca

Wikipedia

focus

hotspot

Apple is now the first public company to be valued at $3 trillion

STAT Summit: Meghan O’Rourke on making chronic illness visible

Peter Hotez and the public health issue of online harassment

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Cancer drug shortages should be causing more outrage

The Karikó problem: Lessons for funding basic research

The cancer drug shortage isn’t new — and neither are the solutions

CRISPR base editing slashes cholesterol levels in monkeys

Duchenne breakthrough therapy leaves behind pioneering families

Health insurers' Q3 question: how much care are people getting?

focus

STAT Readout: Friday, Oct. 20 biotech updates

ADCs take center stage as promising cancer treatments

Medicare innovation center doesn’t save money, experts say

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

CZI to create biohub to build anti

STAT Readout: Friday, Oct. 20 biotech updates

explore

focus

entertainment

hotspot